PeterBio is a brand that specializes in developing innovative gene and cell therapies with a profound impact on people's lives. Guided by four core principles, their priority is to help as many people as possible by creating safe and effective treatments. Their objective is to have an impact on the lives of individuals at a higher risk of developing gene-related diseases.

PeterBio's technologies, namely RITDM™ and T-LOCK™, offer solutions for genetic diseases. With RITDM™, they can correct missing or protective genes' DNA sequences, while T-LOCK™ adapts nature's way to shut down toxic genes. Inspired by individuals who play important roles in our lives, such as family and friends affected by genetic disadvantages or diseases like diabetes, Alzheimer's, Parkinson's, cancer, and CF, PeterBio is dedicated to improving their quality of life.

The brand boasts an experienced team of professionals, including Chief Executive Officer Dirk Hondmann, Chief Scientific Officer Chenzhong Kuang, Senior Vice President Discovery Yan Xiao, and Board Members George Westerkamp. They collaborate with renowned experts like Stuart Orkin, Farren Isaacs, and Louis Kunkel to shape their scientific advisory board. Overall, PeterBio aims to provide nature's solutions to genetic diseases through cutting-edge technologies, driven by a commitment to make a positive difference in people's lives